GoodRx (GDRX)
(Real Time Quote from BATS)
$8.91 USD
0.00 (0.00%)
Updated Jul 24, 2024 11:06 AM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GDRX 8.91 0.00(0.00%)
Will GDRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GDRX
ICLR vs. GDRX: Which Stock Is the Better Value Option?
GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates
Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates
Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Other News for GDRX
GoodRx Holdings Underperform Rating: Concerns Over Biosimilar Affordability and Generic Reimbursement Market Dynamics
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®
GoodRx offers exclusive discount to biosimilar targeting AbbVie’s Humira
Boehringer Ingelheim, GoodRx enter exclusive patient affordability initiative
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), GoodRx Holdings (GDRX) and Organon (OGN)